|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||54.52 - 55.23|
|52 Week Range||42.14 - 67.50|
|Beta (3Y Monthly)||1.22|
|PE Ratio (TTM)||76.54|
|Earnings Date||Apr 23, 2019 - Apr 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||60.79|
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Integra LifeSciences Holdings Corp NASDAQ/NGS:IARTView full report here! Summary * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for IART with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold IART had net inflows of $4.67 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Despite facing adverse foreign exchange volatility across its international business, Integra LifeSciences (IART) can successfully eye certain key developments on foreign shores.
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examplesRead More...
PLAINSBORO, N.J. and TOKYO, March 14, 2019 -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a global leader in medical technology, announces the recent approval of.
Medical device maker Integra Lifesciences Holdings Corp said on Monday it had received a warning letter from the U.S. Food and Drug Administration regarding its manufacturing facility in Boston. The warning letter was issued after an inspection held at the facility in October and November last year, and flags issues related to its quality systems, the company said https://www.sec.gov/Archives/edgar/data/917520/000091752019000015/a8-kfiledmarch112019.htm. Sales of products manufactured in the Boston facility made up less than 4 percent of the company's revenue in 2018, Integra said, adding that it does not expect to incur material incremental expense related resolving the issues.
PLAINSBORO, N.J., March 07, 2019 -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will present at the following.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Mid-caps stocks, like Integra LifeSciences Holdings Corporation (NASDAQ:IART) with aRead More...
Integra (IART) delivered earnings and revenue surprises of 4.84% and 0.56%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 20) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Gossamer ...
On a per-share basis, the Plainsboro, New Jersey-based company said it had net income of 29 cents. Earnings, adjusted for non-recurring costs, were 65 cents per share. The results beat Wall Street expectations. ...
Fourth Quarter 2018 reported revenue increased 4.0% to $383.3 million; organic revenue increased 4.4% Fourth.
Integra (IART) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PLAINSBORO, N.J., Feb. 13, 2019 -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the launch of the.
Want to help shape the future of investing tools? Participate in a short research study and receive a subscription valued at $60. Today we are going to look at Integra Read More...
PLAINSBORO, N.J., Jan. 31, 2019 -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and.
The latest launch reflects Integra LifeSciences' (IART) consistent efforts to boost the Orthopedics and Tissue Technologies segment.
NEW YORK, Jan. 10, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
PLAINSBORO, N.J., Jan. 10, 2019 -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, today announced the full market release.